Stock 4132 GOLDEN BIOTECHNOLOGY CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Financials Golden Biotechnology Corporation

Equities

4132

TW0004132006

Biotechnology & Medical Research

End-of-day quote Taipei Exchange
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
28.9 TWD -0.52% Intraday chart for Golden Biotechnology Corporation +2.30% -26.37%
Jan. 18 Golden Biotechnology Corp. Unveils the Findings of Its Phase II Clinical Trial Investigating Antroquinonol CI
2023 Golden Biotechnology Corporation Reports Earnings Results for the Half Year Ended June 30, 2023 CI

Valuation

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Capitalization 1 4,545 3,237 3,874 6,459 17,123 8,548
Enterprise Value (EV) 1 4,254 3,115 3,948 6,285 16,685 8,309
P/E ratio -13.6 x -9.27 x -13.5 x -15.7 x -38.7 x -31.4 x
Yield - - - - - -
Capitalization / Revenue 43.7 x 35.5 x 46.5 x 72.7 x 209 x 39.2 x
EV / Revenue 40.9 x 34.1 x 47.4 x 70.8 x 204 x 38.1 x
EV / EBITDA -16.1 x -10.8 x -17.6 x -20.4 x -43.2 x -32.2 x
EV / FCF -15.5 x -15.6 x -49.4 x -36.7 x -126 x -84.1 x
FCF Yield -6.44% -6.42% -2.03% -2.72% -0.8% -1.19%
Price to Book 3.84 x 3.6 x 5.68 x 7.34 x 17.8 x 11.2 x
Nbr of stocks (in thousands) 112,216 114,032 115,757 132,227 132,227 142,227
Reference price 2 40.50 28.39 33.47 48.85 129.5 60.10
Announcement Date 3/26/18 4/11/19 4/1/20 3/30/21 4/28/22 4/28/23
1TWD in Million2TWD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales 1 104 91.28 83.29 88.82 81.77 217.8
EBITDA 1 -264.8 -289 -224.3 -307.8 -386.2 -258.2
EBIT 1 -312.7 -334.6 -270.5 -347.9 -423.8 -296.8
Operating Margin -300.69% -366.52% -324.71% -391.71% -518.35% -136.24%
Earnings before Tax (EBT) 1 -325.5 -343.7 -285 -388.8 -441.5 -271.8
Net income 1 -326.9 -343.8 -285.1 -391.4 -443.8 -271.9
Net margin -314.32% -376.6% -342.31% -440.61% -542.8% -124.81%
EPS 2 -2.982 -3.063 -2.480 -3.114 -3.350 -1.912
Free Cash Flow 1 -274 -199.8 -79.98 -171.1 -132.7 -98.85
FCF margin -263.48% -218.9% -96.02% -192.59% -162.24% -45.38%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 3/26/18 4/11/19 4/1/20 3/30/21 4/28/22 4/28/23
1TWD in Million2TWD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 - - 73.8 - - -
Net Cash position 1 291 123 - 174 438 239
Leverage (Debt/EBITDA) - - -0.3289 x - - -
Free Cash Flow 1 -274 -200 -80 -171 -133 -98.8
ROE (net income / shareholders' equity) -29.6% -33% -36.1% -50.1% -46.3% -30.2%
ROA (Net income/ Total Assets) -14.4% -16.6% -16.1% -20.1% -19.8% -14.3%
Assets 1 2,264 2,071 1,770 1,945 2,239 1,899
Book Value Per Share 2 10.60 7.890 5.900 6.660 7.280 5.380
Cash Flow per Share 2 4.100 2.170 1.190 3.240 5.140 3.680
Capex 1 13.2 34.9 10.9 11.5 9.34 14.4
Capex / Sales 12.72% 38.25% 13.08% 12.97% 11.43% 6.61%
Announcement Date 3/26/18 4/11/19 4/1/20 3/30/21 4/28/22 4/28/23
1TWD in Million2TWD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
GOLDEN BIOTECHNOLOGY CORPORATION Stock Golden Biotechnology Corporation
-26.37% 126M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 4132 Stock
  4. Financials Golden Biotechnology Corporation